Copper Development Association
COPPER.org
June 2000
Medical
Uses of Copper in Antiquity
Copper Applications in
Health & Environment
The first recorded medical use of copper is found in the Smith
Papyrus, one of the oldest books known. The Papyrus is an
Egyptian medical text, written between 2600 and 2200 B.C., which
records the use of copper to sterilize chest wounds and to
sterilize drinking water. Other early reports of copper's
medicinal uses are found in the Ebers Papyrus, written around
1500 B.C. The Ebers Papyrus documents medicine practiced in
ancient Egypt and in other cultures that flourished many
centuries earlier. Copper compounds were recommended for
headaches, "trembling of the limbs" (perhaps referring to
epilepsy or St. Vitus' Dance), burn wounds, itching and certain
growths in the neck, some of which were probably boils. Forms of
copper used for the treatment of disease ranged from metallic
copper splinters and shavings to various naturally occurring
copper salts and oxides. A "green pigment" is spoken of which
was probably the mineral, malachite, a form of copper carbonate.
It could also have been chrysocolla, a copper silicate, or even
copper chloride, which forms on copper exposed to seawater. In
the first century A.D., Dioscorides, in his book De Materia
Medica, described a method of making another green pigment known
as verdigris by exposing metallic copper to the vapors of
boiling vinegar. In this process, blue-green copper acetate
forms on the copper surface. Verdigris and blue vitriol (copper
sulfate) were used, among other things, in remedies for eye
ailments such as bloodshot eyes, inflamed or "bleary" eyes, "fat
in the eyes" (trachoma?), and cataracts.
In the Hippocratic Collection (named for, although not entirely
written by, the Greek physician Hippocrates, 460 to 380 B.C.),
copper is recommended for the treatment of leg ulcers associated
with varicose veins. To prevent infection of fresh wounds, the
Greeks sprinkled a dry powder composed of copper oxide and
copper sulfate on the wound. Another antiseptic wound treatment
at the time was a boiled mixture of honey and red copper oxide.
The Greeks had easy access to copper since the metal was readily
available on the island of Kypros (Cyprus) from which the Latin
name for copper, cuprum, is derived.
By the time the Roman physician Aulus Cornelius Celsus began
practicing medicine, during the reign of Tiberius (14 to 37
A.D.), copper and its derivatives had been firmly established as
an important drug in the medical practitioner's pharmacopoeia.
In Celsus' series, De Medicina, books one through six list many
purposes for which copper was used together with the preparation
and the form of copper most effective for each ailment. For the
treatment of venereal disease, for example, Celsus prescribed a
remedy consisting of pepper, myrrh, saffron, cooked antimony
sulfide, and copper oxide. These were first pounded together in
dry wine and when dry, once again pounded together in raisin
wine and heated until dry. For a non-healing chronic ulcer,
treatment consisted of copper oxide and other ingredients
including enough rose oil to give a soft consistency.
Pliny (23 to 79 A.D.) described a number of remedies involving
copper. Black copper oxide was given with honey to remove
intestinal worms. Diluted and injected as drops into nostrils,
it cleared the head and, when taken with honey or honey water,
it purged the stomach. It was given for "eye roughness," "eye
pain and mistiness," and ulceration of the mouth. It was blown
into the ears to relieve ear problems.
In the New World the Aztecs also used copper for medical
purposes. Don Francisco de Mendoza commissioned two learned
Aztec Indian physicians to record the pharmacological treatments
known by the Aztecs at the time of the Conquest. For the
treatment of "Faucium Calor" (literally, heat of the throat, or,
sore throat) they prescribed gargling with a mixture of
ingredients containing copper.
Copper was also employed in ancient India and Persia to treat
lung diseases. The tenth century book, Liber Fundamentorum
Pharmacologiae describes the use of copper compounds for
medicinal purposes in ancient Persia. Powdered malachite was
sprinkled on boils, copper acetate as well as and copper oxide
were used for diseases of the eye and for the elimination of
"yellow bile." Nomadic Mongolian tribes treated and healed
ulcers of venereal origin with orally administered copper
sulfate.
Turning to more modern times, the first observation of copper's
role in the immune system was published in 1867 when it was
reported that, during the cholera epidemics in Paris of 1832,
1849 and 1852, copper workers were immune to the disease. More
recently copper's role in the immune system has been supported
by observations that individuals suffering from Menke's disease
(an inherited disease in which there is defective copper
absorption and metabolism) generally die of immune
system-related phenomena and other infections. Further, animals
deficient in copper have been shown to have increased
susceptibility to bacterial pathogens such as Salmonella and
Listeria. Evidence such as this has led researchers to suggest
strongly that copper compounds not only cure disease but also
aid in the prevention of disease.
In 1885, the French physician, Luton, reported on using copper
acetate in his practice to treat arthritic patients. For
external application he made a salve of hog's lard and 30%
neutral copper acetate. For internal treatment, he used pills
containing 10 mg. of copper acetate. In 1895, Kobert published
his review of the pharmacological actions of copper compounds.
Copper arsenate had been used to treat acute and chronic
diarrhea as well as dysentery and cholera. A variety of
inorganic copper preparations were found to be effective in
treating chronic adenitis, eczema, impetigo, scorphulosis,
tubercular infections, lupus, syphilis, anemias, chorea and
facial neuralgia. An organic complex of copper developed by
Bayer was shown to have curative powers in the treatment of
tuberculosis. Copper treatment for tuberculosis continued until
the 1940s, and various physicians reported on their success in
using copper preparations in intravenous injections.
In 1939, the German physician, Werner Hangarter, noticed that
Finnish copper miners were unaffected by arthritis as long as
they worked in the mining industry. This was particularly
striking since rheumatism was a widespread disease in Finland,
and workers in other industries and other towns had more
rheumatic diseases than did the copper miners. This observation
led Finnish medical researchers plus the Germans, Hangarter and
Lübke, to begin their now classic clinical trials using an
aqueous mixture of copper chloride and sodium salicylate. They
successfully treated patients suffering from rheumatic fever,
rheumatoid arthritis, neck and back problems, as well as
sciatica.
Until recently, just as in Pliny's time, the medical profession
used copper sulfate as a means to clinically induce vomiting.
This is based on the fact that one of the body's natural
physiological responses to prevent copper intoxication is
vomiting. A Manual of Pharmacology and its Applications to
Therapeutics and Toxicology, published by W. B. Saunders Company
in 1957 recommends the use of 0.5 gram of copper sulfate,
dissolved in a glass of water, in a single dose, or three doses
of 0.25 gram fifteen minutes apart, for this purpose.
Since 1934, it has been known that individuals suffering from
such diseases as scarlet fever, diphtheria, tuberculosis,
arthritis, malignant tumors and lymphogranulomas exhibit an
elevation of copper in their blood plasma. Since then, the list
of maladies bringing about such elevation has been extended to
fever, wounds, ulcers, pain, seizures, cancers, carcinogenesis,
diabetes, cerebrovascular and cardiovascular diseases, and
irradiation and tissue stresses, including restricted blood
flow. This suggests that this redistribution of copper in the
body has a general role in responding to physiological, disease,
or injury stress. On the other hand, the elevation of copper in
the affected organ has led some to postulate that it was this
excess of copper that caused the disease. Nonetheless, this
elevation of copper in diseased states is suggested to account
for the natural synthesis of copper-dependent regulatory
proteins and enzymes in the body required for biochemical
responses to stress. It may be that these natural copper
complexes expedite the relief of stress and the repair of
tissues. Thus, it appears that in addition to the anti-bacterial
and anti-fungal activity of inorganic copper compounds as
recognized by the ancients, metallo-organic complexes of copper
have medicinal capabilities that are fundamental to the healing
process itself.
Copper is known to be an essential element in human metabolism.
However, copper does not exist in the body in measurable amounts
in ionic form. All measurable amounts of copper in the body
exist in tissues as complexes with the organic compounds of
proteins and enzymes. Therefore, it has been concluded that
copper becomes and remains intimately involved in body
processes. Some copper complexes serve to store copper, others
to transport it, and yet others play important roles in key
cellular and metabolic processes. Studies into the roles that
these copper complexes play and the mechanisms of these roles
have further confirmed that copper enters into the prevention
and control of a number of disease states in the body. As will
be discussed below, the key to the effective use of copper-based
pharmaceuticals is not the use of inorganic compounds of copper,
as used by the ancients, but rather the use of metallo-organic
complexes or chelates of copper. The process of chelating metals
allows them to be smuggled in the transport process across the
intestinal wall and thereby enter into the mainstream of
nutrient flow and usage in the body.
The first modern research on the subject of copper medicinal
substances was by Professor John R. J. Sorenson, of the
University of Arkansas for Medical Sciences, College of
Pharmacy, who, in 1966, demonstrated that copper complexes have
therapeutic efficacy in the treatment of inflammatory diseases
using doses that are nontoxic. Since then, copper
metallo-organic complexes have been used to successfully treat
patients with arthritic and other chronic degenerative diseases.
More than 140 copper complexes of non-steroidal
anti-inflammatory agents (aspirin and ibuprofen, for example)
have been shown to be more active than their parent compounds.
Copper aspirinate has been shown not only to be more effective
in the treatment of rheumatoid arthritis than aspirin alone, but
it has been shown to prevent or even cure the ulceration of the
stomach often associated with aspirin therapy. Based on these
experiences, the work of Professor Sorenson and other
researchers around the world has progressed into the medicinal
benefits of organic complexes of copper in a number of disease
states. This work, thus far mainly based on animal research, has
opened a whole new vista both into the understanding of copper's
many-fold role in the body and in the practicality of using
supplementary copper in the treatment of wound healing and
inflammation-related disease states. Some of these potential
indications are:
Ulcer and Wound-Healing Activities
of Copper Complexes
It has been demonstrated that copper complexes such as copper
aspirinate and copper tryptophanate, markedly increase healing
rate of ulcers and wounds. For example, copper complexes heal
gastric ulcers five days sooner than other reagents. Further, it
has been shown that, whereas non-steroidal anti-inflammatory
drugs, such as ibuprofen and enefenamic acid suppress wound
healing, copper complexes of these drugs promote normal wound
healing while at the same time retaining anti-inflammatory
activity.
Anticonvulsant Activities of Copper
Complexes
The brain contains more copper than any other organ of the body
except the liver, where copper is stored for use elsewhere. This
fact suggests that copper plays a role in brain functions. With
reports of seizures in animals and humans following the
protracted consumption of copper-deficient diets, it was
reasoned that copper has a role to play in the prevention of
seizures. It was subsequently discovered that organic compounds
that are not themselves anti-convulsants exhibit anticonvulsant
activity when complexed with copper. Further, it was found that
copper complexes of all anti-epileptic drugs are more effective
and less toxic than their parent drugs.
Anticancer Activities of Copper
Complexes
As early as 1912, patients in Germany were treated for facial
epithelioma with a mixture of copper chloride and lecithin.
Success of such treatment suggested that copper compounds have
anticancer activity. Work at the University of Liverpool in 1913
demonstrated that subcutaneous and intravenous injections of a
copper salt or colloidal copper softened and degenerated
carcinomas transplanted into mice. In 1930, work in France
indicated that injections of colloidal copper mobilized and
expelled tumor tissue. Recent work with mice in the USA has
shown that, indeed, treatment of solid tumors with non-toxic
doses of various organic complexes of copper markedly decreased
tumor growth and metastasis and thus increased survival rate.
These copper complexes did not kill cancer cells but caused them
to revert to normal cells.
Anticarcinogenic Activity of Copper
Complexes
Based on work in the treatment of cancers using copper
complexes, researchers have found that these same complexes may
prevent or retard the development of cancers in mice under
conditions where cancers are expected to be induced.
Radiation Protection and Radiation
Recovery of Copper Complexes
Ionizing radiation, such as that used in the treatment of
cancer, has been shown to induce massive systemic inflammation.
Ideally, such radiation-induced injury might be prevented or
ameliorated by chemical repair mechanisms in the body. Thus,
pharmacological approaches to the repair of radiation-damaged
tissue are needed. As early as 1984, copper metallo-organic
complexes have been shown to have radiation protection and
radiation recovery activities. They are capable of causing rapid
recovery of immunocompetence and recovery from radiation induced
tissue changes. The mechanism of this activity appears to be
tied to the ability of certain copper complexes to deactivate
the superoxide, or "free," radicals liberated by ionizing
radiation. In addition, since radiation has the capability of
breaking the bonds of natural copper enzymes in the body,
supplementing these with non-toxic doses of pharmaceutical
copper complexes restores the lost tissue-repair capability.
Since these complexes may also have anticarcinogenic activity,
it is suggested that there would be merit in using copper
complexes in the treatment of cancer and in particular, treating
patients undergoing ionizing radiation therapy for their cancer,
accidental exposure to radiation, and astronauts undertaking
space travel.
Heart Disease and Copper Complexes
Numerous studies have drawn attention to the relationship
between copper deficiency and heart disease. First observed in
rats in 1936, this effect has now been traced to both a
deficiency in copper and an imbalance in the copper-to-zinc
ratio in the body. Work by Dr. L.M. Klevay at the U.S.
Department of Agriculture, Human Nutrition Research Center in
1973 has led to the postulation that copper has a direct effect
on the control of cholesterol. In continuing work published in
1975, he theorized that a metabolic imbalance between zinc and
copper - with more emphasis on copper deficiency than zinc
excess - is a major contributing factor to the etiology of
coronary heart disease. Subsequent work by other investigators
has shown that copper complexes also can have a valuable role in
the minimization of damage to the aorta and heart muscle as
oxygenated blood reperfuses into tissues following myocardial
infarction. This action is based on the anti-inflammatory action
of copper complexes. These and other studies suggest the use of
copper dietary supplements as a means of preventing and
controlling such diseases as atherosclerosis (a form of
arteriosclerosis), coronary heart disease, aortic aneurysms and
myocardial infarction. It has been speculated that the reason
that the heart attack rate in France is lower than in the rest
of Europe is because of the French practice of drinking red
wine. Red wine has a higher copper content than white wine
because it is prepared with the skin of the grape intact. The
copper originates in the wine from the copper fungicides used on
the grapes in the field.
Based on an abundance of historical data such as the foregoing,
many researchers anticipate that copper will become an
increasingly important component of tomorrow's medical
treatments.
References
The historical part of this paper is based on H.H.A. Dollwet and
J.R.J. Sorenson, Historic uses of copper compounds in medicine,
Trace Elements in Medicine, Vol. 2, No. 2, 1985, pp 80 - 87.
http://en.wikipedia.org/w/index.php?title=Copper_aspirinate&oldid=465679308
Copper
Aspirinate
IUPAC name -- dicopper 2-acetyloxybenzoate
Other names --
tetrakis-µ-acetylsalicylato-dicopper(II), copper(II) aspirinate,
cupric acetylsalicylate, cupric aspirinate, cupric aspirin
complex
Identifiers
CAS number -- 23642-01-5 YesY
PubChem -- 92244
Properties
Copper(II) aspirinate is an aspirin chelate of copper(II)
cations (Cu2+). It is used to treat rheumatoid arthritis.
Molecular formula C36H28Cu2O16
Molar mass 843.69g/mol
Appearance Bright blue crystalline solid.
Melting point 248-255 °C (decomp.)
Related compounds -- Aspirin ; Other cations -- Zinc
aspirinate, Aluminium aspirinate
Except where noted otherwise, data are given for materials in
their standard state (at 25 °C, 100 kPa)
Preparation
Copper aspirinate can be prepared by several methods. In one
route of preparation, an excess of acetylsalicylic acid is
dissolved in aqueous sodium carbonate. Sodium hydroxide is not
suitable for this purpose, because it will hydrolyse
acetylsalicylic acid (ASA) into salicylic acid and sodium
acetate.
2 HC9H7O4 + Na2CO3 ? 2 NaC9H7O4 + CO2? + H2O
The resulting solution is then filtered to remove any
undissolved acetylsalicylic acid and is mixed with a solution
containing Cu2+ cations (copper(II) sulfate is suitable),
precipitating bright blue crystals of copper aspirinate
immediately. The crystals can then be filtered from solution,
washed, and dried. An excess of acetylsalicylic acid is used in
the first step, because it eliminates the possibility of
unreacted carbonate anions precipitating the copper in this
step.
4 NaC9H7O4 + 2 CuSO4 ? C36H28Cu2O16? + 2 Na2SO4
Medicinal Use
Copper aspirinate has been proven effective as a treatment for rheumatoid arthritis.[1] The
studies on animal models suggest that copper aspirinate is very
promising in treating against thrombotic
diseases and it has all the prospects of success in
becoming an antithrombotic drug that prevents and treats
thrombotic diseases in humans.[2]
Other uses
The use of copper aspirinate as a pigment in PVC and Polystyrene
has also been investigated.[3]
Footnotes
1. ^ "Rheumatoid Arthritis (RA)". Copper Development
Association. June 2000.
http://www.copper.org/innovations/2000/06/medicine-chest.html.
2. ^ Weiping Liu,corresponding author1 Huizhou Xiong, Yikun Yang
Ling Li, Zhiqiang Shen, and Zhihe Chen (1998). "Potential
Application of Copper Aspirinate in Preventing and Treating
Thromboembolic Diseases". Met Based Drugs. (Hindawi Publishing
Corporation) 5 (3): 123–126. doi:10.1155/MBD.1998.123. PMC
2365110. PMID 18475833.
http://www.copper.org/innovations/2000/06/medicine-chest.html.
3. ^ Allan, J R; A Renton, W E Smith, D L Gerrard, J Birnie
(1991). "A Study of the Performance of Bis(acetylsalicylate)
Copper(II) and the Cobalt(II), Nickel(II) and Copper(II)
Complexes of Pyridine-3,4-dicarboxylic Acid as Colouring
Materials for Poly(vinyl chloride) and Polystyrene". Eur. Polym.
J. 27 (7): 669–672. doi:10.1016/0014-3057(91)90155-H.
Salicylates
Salicylic acid
Aspirin
Aloxiprin
Methyl salicylate
Magnesium salicylate
Ethyl salicylate
Bismuth subsalicylate
Sodium salicylate
Salicylamide
Salicin
Benorilate
Salsalate
Ethenzamide
Diflunisal
Trolamine salicylate
Homosalate
Salicylmethylecgonine
Octyl salicylate
Aluminon
Benzyl salicylate
Copper aspirinate
Potassium salicylate